TY - JOUR AU - Wersall, P. J. AU - Blomgren, H. AU - Lax, I. PY - 2005 DA - 2005// TI - Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma JO - Radiother Oncol VL - 77 UR - https://doi.org/10.1016/j.radonc.2005.03.022 DO - 10.1016/j.radonc.2005.03.022 ID - Wersall2005 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2015 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21254 DO - 10.3322/caac.21254 ID - Siegel2015 ER - TY - JOUR AU - Motzer, R. J. AU - Basch, E. PY - 2007 DA - 2007// TI - Targeted drugs for metastatic renal cell carcinoma JO - Lancet VL - 370 UR - https://doi.org/10.1016/S0140-6736(07)61874-1 DO - 10.1016/S0140-6736(07)61874-1 ID - Motzer2007 ER - TY - JOUR AU - Escudier, B. AU - Pluzanska, A. AU - Koralewski, P. PY - 2007 DA - 2007// TI - AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial JO - Lancet VL - 370 UR - https://doi.org/10.1016/S0140-6736(07)61904-7 DO - 10.1016/S0140-6736(07)61904-7 ID - Escudier2007 ER - TY - JOUR AU - Negrier, S. AU - Escudier, B. AU - Lasset, C. PY - 1998 DA - 1998// TI - Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma JO - N Engl J Med VL - 338 UR - https://doi.org/10.1056/NEJM199804303381805 DO - 10.1056/NEJM199804303381805 ID - Negrier1998 ER - TY - JOUR AU - Escudier, B. AU - Desai, A. A. AU - Rolland, F. PY - 2007 DA - 2007// TI - Sorafenib in advanced clear-cell renal-cell carcinoma JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa060655 DO - 10.1056/NEJMoa060655 ID - Escudier2007 ER - TY - JOUR AU - Hutson, T. E. AU - Escudier, B. AU - Esteban, E. PY - 2014 DA - 2014// TI - Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.50.3961 DO - 10.1200/JCO.2013.50.3961 ID - Hutson2014 ER - TY - JOUR AU - Motzer, R. J. AU - Hutson, T. E. AU - Tomczak, P. PY - 2007 DA - 2007// TI - Sunitinib versus interferon alfa in metastatic renal-cell carcinoma JO - Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa065044 DO - 10.1056/NEJMoa065044 ID - Motzer2007 ER - TY - JOUR AU - Sternberg, C. N. AU - Hawkins, R. E. AU - Wagstaff, J. PY - 2013 DA - 2013// TI - A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.12.010 DO - 10.1016/j.ejca.2012.12.010 ID - Sternberg2013 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - Oudard, S. PY - 2010 DA - 2010// TI - RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.25219 DO - 10.1002/cncr.25219 ID - Motzer2010 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - Tomczak, P. PY - 2013 DA - 2013// TI - Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70093-7 DO - 10.1016/S1470-2045(13)70093-7 ID - Motzer2013 ER - TY - JOUR AU - Scher, H. I. AU - Halabi, S. AU - Tannock, I. PY - 2008 DA - 2008// TI - Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.12.4487 DO - 10.1200/JCO.2007.12.4487 ID - Scher2008 ER - TY - JOUR AU - Wilson, M. K. AU - Karakasis, K. AU - Oza, A. M. PY - 2015 DA - 2015// TI - Outcomes and endpoints in trials of cancer treatment: the past, present, and future JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)70375-4 DO - 10.1016/S1470-2045(14)70375-4 ID - Wilson2015 ER - TY - JOUR AU - Pazdur, R. PY - 2008 DA - 2008// TI - Endpoints for assessing drug activity in clinical trials JO - Oncologist VL - 13 UR - https://doi.org/10.1634/theoncologist.13-S2-19 DO - 10.1634/theoncologist.13-S2-19 ID - Pazdur2008 ER - TY - JOUR AU - Hutson, T. E. AU - Lesovoy, V. AU - Al-Shukri, S. PY - 2013 DA - 2013// TI - Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70465-0 DO - 10.1016/S1470-2045(13)70465-0 ID - Hutson2013 ER - TY - JOUR AU - Motzer, R. J. AU - Hutson, T. E. AU - Cella, D. PY - 2013 DA - 2013// TI - Pazopanib versus sunitinib in metastatic renal-cell carcinoma JO - Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1303989 DO - 10.1056/NEJMoa1303989 ID - Motzer2013 ER - TY - STD TI - Sherman S, Amzal B, Calvo E, et al. An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed. Clin Ther. 2015. ID - ref17 ER - TY - JOUR AU - Zanardi, E. AU - Verzoni, E. AU - Grassi, P. PY - 2015 DA - 2015// TI - Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma JO - Ther Adv Urol VL - 7 UR - https://doi.org/10.1177/1756287215574457 DO - 10.1177/1756287215574457 ID - Zanardi2015 ER - TY - JOUR AU - Sheng, X. AU - Chi, Z. AU - Cui, C. PY - 2016 DA - 2016// TI - Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis JO - Oncotarget VL - 10;7 ID - Sheng2016 ER - TY - JOUR AU - Park, S. J. AU - Lee, J. L. AU - Park, I. PY - 2012 DA - 2012// TI - Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma JO - Chemotherapy VL - 58 UR - https://doi.org/10.1159/000346484 DO - 10.1159/000346484 ID - Park2012 ER - TY - JOUR AU - Zhao, J. AU - Huang, X. AU - Sun, F. PY - 2014 DA - 2014// TI - Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma JO - Can Urol Assoc J VL - 8 UR - https://doi.org/10.5489/cuaj.2096 DO - 10.5489/cuaj.2096 ID - Zhao2014 ER - TY - JOUR AU - Filson, C. P. AU - Redman, B. G. AU - Dunn, R. L. AU - Miller, D. C. PY - 2011 DA - 2011// TI - Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma JO - Urology VL - 77 UR - https://doi.org/10.1016/j.urology.2010.11.003 DO - 10.1016/j.urology.2010.11.003 ID - Filson2011 ER - TY - JOUR AU - Escudier, B. AU - Szczylik, C. AU - Hutson, T. E. PY - 2009 DA - 2009// TI - Randomized Phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.3342 DO - 10.1200/JCO.2008.19.3342 ID - Escudier2009 ER - TY - JOUR AU - Procopio, G. AU - Derosa, L. AU - Gernone, A. PY - 2014 DA - 2014// TI - Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting JO - Future Oncol VL - 10 UR - https://doi.org/10.2217/fon.14.48 DO - 10.2217/fon.14.48 ID - Procopio2014 ER - TY - JOUR AU - McCann, L. AU - Amit, O. AU - Pandite, L. AU - Amado, R. G. PY - 2010 DA - 2010// TI - An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC) JO - J Clin Oncol VL - 28 ID - McCann2010 ER - TY - JOUR AU - Stadler, W. M. AU - Figlin, R. A. AU - McDermott, D. F. PY - 2010 DA - 2010// TI - Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.24864 DO - 10.1002/cncr.24864 ID - Stadler2010 ER - TY - JOUR AU - Beck, J. AU - Procopio, G. AU - Bajetta, E. PY - 2011 DA - 2011// TI - Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdq651 DO - 10.1093/annonc/mdq651 ID - Beck2011 ER - TY - JOUR AU - Gore, M. E. AU - Szczylik, C. AU - Porta, C. PY - 2015 DA - 2015// TI - Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma JO - Br J Cancer VL - 113 UR - https://doi.org/10.1038/bjc.2015.196 DO - 10.1038/bjc.2015.196 ID - Gore2015 ER - TY - JOUR AU - Bellmunt, J. AU - Fishman, M. AU - Eisen, T. AU - Quinn, D. PY - 2010 DA - 2010// TI - Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients JO - Expert Rev Anticancer Ther VL - 10 UR - https://doi.org/10.1586/era.10.68 DO - 10.1586/era.10.68 ID - Bellmunt2010 ER - TY - JOUR AU - Eisen, T. AU - Oudard, S. AU - Szczylik, C. PY - 2008 DA - 2008// TI - Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial JO - J Natl Cancer Inst VL - 100 UR - https://doi.org/10.1093/jnci/djn319 DO - 10.1093/jnci/djn319 ID - Eisen2008 ER - TY - JOUR AU - Ambring, A. AU - Björholt, I. AU - Lesen, E. AU - Stierner, U. AU - Oden, A. PY - 2013 DA - 2013// TI - Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study JO - Med Oncol VL - 30 UR - https://doi.org/10.1007/s12032-012-0331-8 DO - 10.1007/s12032-012-0331-8 ID - Ambring2013 ER - TY - JOUR AU - Yu, X. AU - Guo, G. AU - Li, X. PY - 2015 DA - 2015// TI - Retrospective analysis of the efficacy and safety of sorafenib in Chinese patients with metastatic renal cell carcinoma and prognostic factors related to overall survival JO - Medicine (Baltimore) VL - 94 UR - https://doi.org/10.1097/MD.0000000000001361 DO - 10.1097/MD.0000000000001361 ID - Yu2015 ER - TY - JOUR AU - Liu, F. AU - Chen, X. AU - Peng, E. PY - 2011 DA - 2011// TI - VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials JO - J Huazhong Univ Sci Technol Med Sci VL - 31 UR - https://doi.org/10.1007/s11596-011-0680-0 DO - 10.1007/s11596-011-0680-0 ID - Liu2011 ER - TY - JOUR AU - Guo, F. AU - Han, T. AU - Liu, Z. PY - 2015 DA - 2015// TI - Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicentre long-term follow-up retrospective study JO - Onco Targets Ther VL - 8 ID - Guo2015 ER - TY - JOUR AU - Kim, S. H. AU - Kim, S. AU - Nam, B. H. PY - 2015 DA - 2015// TI - Efficacy and safety of sorafenib therapy on metastatic renal cell carcinoma in Korean patients: results from a retrospective multicentre study JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0135165 DO - 10.1371/journal.pone.0135165 ID - Kim2015 ER - TY - JOUR AU - Tan, X. AU - Liu, Y. AU - Hou, J. AU - Cao, G. PY - 2015 DA - 2015// TI - Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus JO - Onco Targets Ther VL - 8 ID - Tan2015 ER - TY - JOUR AU - Ye, D. W. AU - Zhang, H. L. PY - 2014 DA - 2014// TI - Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma JO - Onco Targets Ther VL - 7 UR - https://doi.org/10.2147/OTT.S41828 DO - 10.2147/OTT.S41828 ID - Ye2014 ER - TY - JOUR AU - Motzer, R. J. AU - Nosov, D. AU - Eisen, T. PY - 2013 DA - 2013// TI - Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.47.4940 DO - 10.1200/JCO.2012.47.4940 ID - Motzer2013 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - Bukowski, R. PY - 2013 DA - 2013// TI - Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma JO - Br J Cancer VL - 108 UR - https://doi.org/10.1038/bjc.2013.236 DO - 10.1038/bjc.2013.236 ID - Motzer2013 ER - TY - JOUR AU - Yang, L. AU - Shi, L. AU - Fu, Q. AU - Xiong, H. AU - Zhang, M. AU - Yu, S. PY - 2012 DA - 2012// TI - Efficacy and safety of sorafenib in advanced renal cell carcinoma patients: Results from a long-term study JO - Oncol Lett VL - 3 ID - Yang2012 ER -